Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong
- PMID: 32537840
- DOI: 10.1111/hepr.13535
Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong
Abstract
Aim: Non-alcoholic steatohepatitis (NASH) is the progressive form of non-alcoholic fatty liver disease (NAFLD) and prevalence is rising in Asia due to increasing rates of urbanization, sedentary lifestyles, and poor nutrition.
Methods: We built a Markov model with 20-year horizon to estimate the burden of NASH in Hong Kong. Cohort size was determined by population size, prevalence of NAFLD, and incidence of NASH in 2017. Health states include hepatic steatosis, fibrosis stages 0-3, compensated and decompensated cirrhosis, hepatocellular carcinoma, post-liver transplant, and liver-related, cardiovascular, and background mortality. Transition probabilities were estimated from published reports and we converted 2017 Gazette price from the Hospital Authority of Hong Kong to US dollars. We discounted costs by 3% annually. Health utilities were assumed to be the same as in the USA.
Results: Non-alcoholic steatohepatitis will cost $1.32 billion and 124 liver transplants over 20 years, with average cost per person-year of $257. Sensitivity analyses show our model is robust in predicting costs for the prevalent population but likely overestimates costs for the incident population.
Conclusions: Non-alcoholic steatohepatitis will contribute to a significant clinical and economic burden in Hong Kong over the next two decades. Due to the limited number of donors and small number of liver transplants undertaken annually, patients with advanced liver disease due to NASH in Hong Kong are more likely to die from NASH than their counterparts in North America and Europe. Thus, rising prevalence of metabolic syndrome in elderly adults in Hong Kong make NASH an important consideration for clinicians and policy makers.
Keywords: East Asia; Hong Kong; Markov model; clinical burden; cost-of-illness modeling; economic burden; hepatic steatosis; liver fibrosis; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis.
© 2020 The Japan Society of Hepatology.
Similar articles
-
Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand.BMC Gastroenterol. 2021 Mar 25;21(1):135. doi: 10.1186/s12876-021-01720-w. BMC Gastroenterol. 2021. PMID: 33765931 Free PMC article.
-
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.Liver Int. 2021 Jun;41(6):1227-1242. doi: 10.1111/liv.14825. Epub 2021 Mar 18. Liver Int. 2021. PMID: 33590598 Free PMC article. Review.
-
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.JHEP Rep. 2020 Jul 15;2(5):100142. doi: 10.1016/j.jhepr.2020.100142. eCollection 2020 Oct. JHEP Rep. 2020. PMID: 32775976 Free PMC article.
-
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.Diabetes Care. 2020 Feb;43(2):283-289. doi: 10.2337/dc19-1113. Epub 2019 Oct 28. Diabetes Care. 2020. PMID: 31658974
-
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263. World J Gastroenterol. 2017. PMID: 29307986 Free PMC article. Review.
Cited by
-
Review and expert opinion on MAFLD, oxidative stress and multifunctional management.Drugs Context. 2024 Jan 10;13:2023-9-3. doi: 10.7573/dic.2023-9-3. eCollection 2024. Drugs Context. 2024. PMID: 38264403 Free PMC article. Review.
-
State transitions across the Strep A disease spectrum: scoping review and evidence gaps.BMC Infect Dis. 2024 Jan 19;24(1):108. doi: 10.1186/s12879-023-08888-4. BMC Infect Dis. 2024. PMID: 38243271 Free PMC article. Review.
-
NAFLD and NAFLD-related HCC in Asia: Burden and Surveillance.J Clin Exp Hepatol. 2024 Jan-Feb;14(1):101213. doi: 10.1016/j.jceh.2023.06.013. Epub 2023 Jul 5. J Clin Exp Hepatol. 2024. PMID: 38076360 Review.
-
Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population.Quant Imaging Med Surg. 2023 Oct 1;13(10):6493-6502. doi: 10.21037/qims-23-511. Epub 2023 Aug 28. Quant Imaging Med Surg. 2023. PMID: 37869309 Free PMC article.
-
Estimating the cost of illness of non-alcoholic fatty liver disease in Bangladesh.JGH Open. 2023 Sep 4;7(9):629-635. doi: 10.1002/jgh3.12960. eCollection 2023 Sep. JGH Open. 2023. PMID: 37744705 Free PMC article.
References
-
- Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357.
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
-
- Li J, Zou B, Yeo YH et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019; 4: 389-398.
-
- Wong VWS, Chu WCW, Wong GLH et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409-415.
-
- Younossi ZM, Stepanova M, Negro F et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012; 91(6): 319-327.
LinkOut - more resources
Full Text Sources